Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAF265 in advanced melanoma
NCT00304525Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2006
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of RAF265 in melanoma (5 arms), sponsored by Novartis. Primary endpoints: Maximum Tolerated Dose, Dose Limiting Toxicities and 3 more. Started Apr 2006; status: completed.
02
Drugs
RAF265
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00304525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00304525.